9/12 5:30 pm - 8:30 pm
HBA presents 'Putting Academia-Industry Research Partnerships to Work.' Novartis, 1 Health Plaza, East Hanover, NJ more
9/24 4:00 pm - 6:00 pm
CURE presents healthcare investment banker Anthony Gibney of Leerink Swann. Yale Anlyan Center, 300 Cedar Street, New Haven more
10/1 4:00 pm - 6:00 pm
CURE/Yale BioHaven presents Trevi Therapeutics. Anlyan Center, 300 Cedar Street, New Haven. Watch for details.
10/8-9 12th annual BIO Investor Forum. The Palace Hotel, San Francisco more
10/15 6:00 pm - 9:30 pm
HBA presents Women's Healthcare Innovation and Leadership Showcase. Sanofi Campus, 55 Corporate Drive Auditorium, Bridgewater, NJ more
11/7 10:00 am - 3:00 pm
CT Innovation Summit. Mentor meetings, awards ceremony, and more. Co-sponsored by CURE. Oakdale Theater, Wallingford more
11/11-13 The BIO Convention in China. National Convention Center, Beijing more
12/3 5:45 pm - 7:30 pm
CURE Holiday Party. 'The best networking in town.' Café George, 300 George Street, New Haven. Save the Date!

Cost-saving discounts for CURE members!
CURE members can now receive discounts on various products and services, such as lab supplies, shipping services, and gases more

GlyGenix Therapeutics, Inc.
15 Research Drive
Woodbridge, CT 06525

Phone: 203-397-3637
Fax: 203-397-5821
Website: http://glygenix.com

Dr. William L. Fodor, Ph.D. - CEO - william.fodor@glygenix.com

General Information
GlyGenix Therapeutics, Inc. (GTI) is focused on treating and curing Glycogen Storage Diseases (GSDs). Our primary focus is to cure GSD type 1a, which is caused by an inherited gene mutation resulting in altered glycogen metabolism and glucose homeostasis. We are currently evaluating in vivo approaches for targeting the normal gene to the appropriate tissue, including Adeno-Associated Viral (AAV) vector mediated gene therapy. The product opportunities target unmet clinical needs and are expected to represent a significant therapeutic advance. GlyGenix Therapeutics, Inc.'s mission is focused on the development of nucleic acid molecules that compensate or correct the genetic defects that cause Glycogen Storage Disease Type 1a.

Research Activities
Glygenix is currently engaged in drug development research activities and together with our scientific advisors have identified a lead drug candidate and are preparing to initiate a formal GLP toxicology study that will enable an Investigational New Drug (IND) application to the FDA.

Other Information
CT Employees: 1
World Employees: 1